REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS

Clinical trials for REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS trials appear

Sign up with your email to follow new studies for REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New cell therapy targets hard-to-treat blood disorders

Disease control Recruiting now

This early-stage study tests a new treatment called RN1201 for people with certain blood disorders caused by the immune system attacking the body's own cells. The treatment involves giving patients specially designed immune cells after a short course of chemotherapy to weaken the…

Matched conditions: REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS

Phase: PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS

Get alerted when new REFRACTORY IMMUNE-MEDIATED PLATELET TRANSFUSION REFRACTORINESS trials appear

New cell therapy targets hard-to-treat blood disorders